Andrew B Katims,Amy L Tin,Melissa Assel,Patrick Hensley,Roger Li,Vitaly Margulis,Surena Matin,Maximilian Pallauf,Roderick K Clark,Jay D Raman,Nirmish Singla,Philippe E Spiess,Jonathan Coleman
{"title":"上尿路癌肾输尿管切除术后非尿路上皮复发的预测因素和模式(UCAN合作)。","authors":"Andrew B Katims,Amy L Tin,Melissa Assel,Patrick Hensley,Roger Li,Vitaly Margulis,Surena Matin,Maximilian Pallauf,Roderick K Clark,Jay D Raman,Nirmish Singla,Philippe E Spiess,Jonathan Coleman","doi":"10.1097/ju.0000000000004646","DOIUrl":null,"url":null,"abstract":"PURPOSE\r\nAfter radical nephroureterectomy for upper tract urothelial carcinoma, 25% of patients experience distant metastasis within 5 years. Non-urothelial recurrence is associated with poor prognosis and survival, with ∼80% of patients dying within 2 years. We evaluated predictors, patterns, and timing of recurrences after radical nephroureterectomy and the association between recurrence location and cancer-specific survival.\r\n\r\nMATERIALS AND METHODS\r\nSeparate competing risk regression models with each site as the outcome and all other recurrence sites as the competing risk. A Cox proportional hazards model evaluated predictors and the association between cancer-specific survival and recurrence site, adjusting for time from surgery to recurrence. A separate model including multiple sites (yes/no) evaluated the association with cancer-specific survival, also adjusting for recurrence sites.\r\n\r\nRESULTS\r\n2177 patients with upper tract urothelial carcinoma underwent radical nephroureterectomy between 01/2000-02/2021 from 7 institutions, with 454 developing non-urothelial recurrence (survivor median follow-up, 34 (IQR 11, 70) months). Improved cancer-specific survival rates were seen in lung and lymph node metastasis compared to other sites (HR 0.60, 95% CI 0.37, 0.97, p = 0.038; HR 0.65, 95% CI 0.41, 1.02, p = 0.063, respectively). Recurrence to multiple concurrent non-urothelial sites was associated with worse cancer-specific survival rates (HR 1.68, 95% CI 1.30, 2.17, p<0.001). Significant recurrence associations included tumor size, high stage/grade, and tumor location. There was no statistically significant survival differences based on timing of recurrence.\r\n\r\nCONCLUSIONS\r\nRecurrences were common within 2 years. Lung/lymph node recurrences portended the most favorable cancer-specific survival rates. Understanding the timing and location of recurrence can tailor surveillance strategies.","PeriodicalId":501636,"journal":{"name":"The Journal of Urology","volume":"145 1","pages":"101097JU0000000000004646"},"PeriodicalIF":0.0000,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Predictors and patterns of non-urothelial recurrence after nephroureterectomy for upper tract urothelial carcinoma (UCAN Collaboration).\",\"authors\":\"Andrew B Katims,Amy L Tin,Melissa Assel,Patrick Hensley,Roger Li,Vitaly Margulis,Surena Matin,Maximilian Pallauf,Roderick K Clark,Jay D Raman,Nirmish Singla,Philippe E Spiess,Jonathan Coleman\",\"doi\":\"10.1097/ju.0000000000004646\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"PURPOSE\\r\\nAfter radical nephroureterectomy for upper tract urothelial carcinoma, 25% of patients experience distant metastasis within 5 years. Non-urothelial recurrence is associated with poor prognosis and survival, with ∼80% of patients dying within 2 years. We evaluated predictors, patterns, and timing of recurrences after radical nephroureterectomy and the association between recurrence location and cancer-specific survival.\\r\\n\\r\\nMATERIALS AND METHODS\\r\\nSeparate competing risk regression models with each site as the outcome and all other recurrence sites as the competing risk. A Cox proportional hazards model evaluated predictors and the association between cancer-specific survival and recurrence site, adjusting for time from surgery to recurrence. A separate model including multiple sites (yes/no) evaluated the association with cancer-specific survival, also adjusting for recurrence sites.\\r\\n\\r\\nRESULTS\\r\\n2177 patients with upper tract urothelial carcinoma underwent radical nephroureterectomy between 01/2000-02/2021 from 7 institutions, with 454 developing non-urothelial recurrence (survivor median follow-up, 34 (IQR 11, 70) months). Improved cancer-specific survival rates were seen in lung and lymph node metastasis compared to other sites (HR 0.60, 95% CI 0.37, 0.97, p = 0.038; HR 0.65, 95% CI 0.41, 1.02, p = 0.063, respectively). Recurrence to multiple concurrent non-urothelial sites was associated with worse cancer-specific survival rates (HR 1.68, 95% CI 1.30, 2.17, p<0.001). Significant recurrence associations included tumor size, high stage/grade, and tumor location. There was no statistically significant survival differences based on timing of recurrence.\\r\\n\\r\\nCONCLUSIONS\\r\\nRecurrences were common within 2 years. Lung/lymph node recurrences portended the most favorable cancer-specific survival rates. Understanding the timing and location of recurrence can tailor surveillance strategies.\",\"PeriodicalId\":501636,\"journal\":{\"name\":\"The Journal of Urology\",\"volume\":\"145 1\",\"pages\":\"101097JU0000000000004646\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-06-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Journal of Urology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1097/ju.0000000000004646\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of Urology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/ju.0000000000004646","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
目的:上尿路癌根治性肾输尿管切除术后,25%的患者在5年内发生远处转移。非尿路上皮复发与不良预后和生存相关,约80%的患者在2年内死亡。我们评估了根治性肾输尿管切除术后复发的预测因素、模式和时间,以及复发部位与癌症特异性生存之间的关系。材料与方法以每个部位为结果,所有其他复发部位为竞争风险,分别建立竞争风险回归模型。Cox比例风险模型评估了预测因素以及癌症特异性生存和复发部位之间的关系,调整了从手术到复发的时间。一个包括多个部位(是/否)的单独模型评估了与癌症特异性生存的关系,也调整了复发部位。结果2000年1月至2021年2月间,来自7家医院的2177例上尿路癌患者接受了根治性肾输尿管切除术,其中454例出现非尿路复发(存活者中位随访时间为34个月)。与其他部位相比,肺癌和淋巴结转移的癌症特异性生存率有所提高(HR 0.60, 95% CI 0.37, 0.97, p = 0.038;HR 0.65, 95% CI 0.41, 1.02, p = 0.063)。并发多个非尿路上皮部位的复发与较差的癌症特异性生存率相关(HR 1.68, 95% CI 1.30, 2.17, p<0.001)。显著的复发关联包括肿瘤大小、高分期/分级和肿瘤位置。基于复发时间的生存差异无统计学意义。结论2年内复发多见。肺/淋巴结复发预示着最有利的癌症特异性生存率。了解复发的时间和地点可以调整监测策略。
Predictors and patterns of non-urothelial recurrence after nephroureterectomy for upper tract urothelial carcinoma (UCAN Collaboration).
PURPOSE
After radical nephroureterectomy for upper tract urothelial carcinoma, 25% of patients experience distant metastasis within 5 years. Non-urothelial recurrence is associated with poor prognosis and survival, with ∼80% of patients dying within 2 years. We evaluated predictors, patterns, and timing of recurrences after radical nephroureterectomy and the association between recurrence location and cancer-specific survival.
MATERIALS AND METHODS
Separate competing risk regression models with each site as the outcome and all other recurrence sites as the competing risk. A Cox proportional hazards model evaluated predictors and the association between cancer-specific survival and recurrence site, adjusting for time from surgery to recurrence. A separate model including multiple sites (yes/no) evaluated the association with cancer-specific survival, also adjusting for recurrence sites.
RESULTS
2177 patients with upper tract urothelial carcinoma underwent radical nephroureterectomy between 01/2000-02/2021 from 7 institutions, with 454 developing non-urothelial recurrence (survivor median follow-up, 34 (IQR 11, 70) months). Improved cancer-specific survival rates were seen in lung and lymph node metastasis compared to other sites (HR 0.60, 95% CI 0.37, 0.97, p = 0.038; HR 0.65, 95% CI 0.41, 1.02, p = 0.063, respectively). Recurrence to multiple concurrent non-urothelial sites was associated with worse cancer-specific survival rates (HR 1.68, 95% CI 1.30, 2.17, p<0.001). Significant recurrence associations included tumor size, high stage/grade, and tumor location. There was no statistically significant survival differences based on timing of recurrence.
CONCLUSIONS
Recurrences were common within 2 years. Lung/lymph node recurrences portended the most favorable cancer-specific survival rates. Understanding the timing and location of recurrence can tailor surveillance strategies.